Literature DB >> 21174059

Altered expression of imprinted genes in Wilms tumors.

Jochen Hubertus1, Martin Lacher, Marietta Rottenkolber, Josef Müller-Höcker, Michael Berger, Maximilian Stehr, Dietrich von Schweinitz, Roland Kappler.   

Abstract

Overexpression of insulin-like growth factor 2 (IGF2), an imprinted gene located on chromosome 11p15, has been reported as a characteristic feature in various embryonal tumors, including Wilms tumor (WT). Recent studies specified loss of imprinting (LOI) in a differential methylated region (DMR) of the IGF2/H19 cluster or loss of heterozygosity (LOH), respectively, uniparental disomy (UPD) being responsible for this overexpression. However, the role of other imprinted genes in the genesis of WT is still unknown. In the current study, we analyzed transcriptional activity of the imprinted genes IGF2, H19, NNAT, DLK1, RTL1, MEG3, and MEST as well as the methylation status of the DMR of the IGF2/H19 cluster in a panel of 32 WTs. Except for H19, we detected massive overexpression of all genes in the majority of WTs compared to normal renal tissue, which was most prominent for the paternally expressed genes IGF2, NNAT, and MEST. Alterations of the H19DMR were found in two-thirds of the WTs. Moreover, we have seen a strong correlation between the transcriptional activity of IGF2, NNAT and MEST and LOI/LOH of H19DMR, which was inverse for H19. Expression of DLK1, RTL1 and MEG3 does not correlate with LOI/LOH of H19DMR. Altogether, our findings suggest that over-expression of imprinted genes is common in WTs and correlates at least for some imprinted genes with LOI of H19DMR. Thus, it may be speculated that alterations of the DNA modification machinery drive erroneous setting of methylation marks in imprinting regions throughout the genome, which leads to the concomitant activation of imprinted genes in blastomagenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21174059     DOI: 10.3892/or.2010.1113

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  17 in total

Review 1.  Specific changes in the expression of imprinted genes in prostate cancer--implications for cancer progression and epigenetic regulation.

Authors:  Teodora Ribarska; Klaus-Marius Bastian; Annemarie Koch; Wolfgang A Schulz
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 2.  The human imprintome: regulatory mechanisms, methods of ascertainment, and roles in disease susceptibility.

Authors:  David A Skaar; Yue Li; Autumn J Bernal; Cathrine Hoyo; Susan K Murphy; Randy L Jirtle
Journal:  ILAR J       Date:  2012

3.  Association of FOXM1 expression with tumor histology and prognosis in Wilms tumor: Potential for a new prognostic marker.

Authors:  Nadja Apelt; Jochen Hubertus; Doris Mayr; Norbert Graf; Rhoikos Furtwängler; Dietrich Von Schweinitz; Roland Kappler
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

4.  Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer.

Authors:  Mark B Leick; Christopher J Shoff; Erwin C Wang; Jaclyn L Congress; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2011-08-19

5.  Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.

Authors:  Amei Schweigert; Carmen Fischer; Doris Mayr; Dietrich von Schweinitz; Roland Kappler; Jochen Hubertus
Journal:  Pediatr Surg Int       Date:  2016-09-27       Impact factor: 1.827

6.  MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1.

Authors:  Jiang Yan; Xiaoqiang Guo; Jiazeng Xia; Tin Shan; Chen Gu; Zheng Liang; Wei Zhao; Shimao Jin
Journal:  Med Oncol       Date:  2014-02-11       Impact factor: 3.064

7.  Shared Copy Number Variation in Simultaneous Nephroblastoma and Neuroblastoma due to Fanconi Anemia.

Authors:  A Serra; K Eirich; A K Winkler; K Mrasek; G Göhring; G Barbi; H Cario; B Schlegelberger; B Pokora; T Liehr; C Leriche; D Henne-Bruns; T F Barth; D Schindler
Journal:  Mol Syndromol       Date:  2012-08-23

8.  The protein p17 signaling pathways in cancer.

Authors:  Klaus Heese
Journal:  Tumour Biol       Date:  2013-07-31

9.  Selective methylation of CpGs at regulatory binding sites controls NNAT expression in Wilms tumors.

Authors:  Jochen Hubertus; Ferdinand Zitzmann; Franziska Trippel; Josef Müller-Höcker; Maximilian Stehr; Dietrich von Schweinitz; Roland Kappler
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 10.  The yin and yang of kidney development and Wilms' tumors.

Authors:  Peter Hohenstein; Kathy Pritchard-Jones; Jocelyn Charlton
Journal:  Genes Dev       Date:  2015-03-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.